BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rudd GD, Haverkamp W, Mason JW, Wenger T, Jay G, Hebert D, Doty P, Horstmann R. Lacosamide cardiac safety: clinical trials in patients with partial-onset seizures. Acta Neurol Scand 2015;132:355-63. [DOI: 10.1111/ane.12414] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Moavero R, Pisani LR, Pisani F, Curatolo P. Safety and tolerability profile of new antiepileptic drug treatment in children with epilepsy. Expert Opin Drug Saf 2018;17:1015-28. [PMID: 30169997 DOI: 10.1080/14740338.2018.1518427] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
2 Del Bianco C, Placidi F, Liguori C, Mari L, Ulivi M, Ornello R, Pisani A, Mercuri NB, Izzi F. Long-term efficacy and safety of lacosamide and levetiracetam monotherapy in elderly patients with focal epilepsy: A retrospective study. Epilepsy & Behavior 2019;94:178-82. [DOI: 10.1016/j.yebeh.2019.02.022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Strzelczyk A, Zöllner JP, Willems LM, Jost J, Paule E, Schubert-Bast S, Rosenow F, Bauer S. Lacosamide in status epilepticus: Systematic review of current evidence. Epilepsia 2017;58:933-50. [PMID: 28295226 DOI: 10.1111/epi.13716] [Cited by in Crossref: 63] [Cited by in F6Publishing: 42] [Article Influence: 12.6] [Reference Citation Analysis]
4 Steinhoff BJ, Eckhardt K, Doty P, De Backer M, Brunnert M, Schulze-Bonhage A. A long-term noninterventional safety study of adjunctive lacosamide therapy in patients with epilepsy and uncontrolled partial-onset seizures. Epilepsy Behav 2016;58:35-43. [PMID: 27054272 DOI: 10.1016/j.yebeh.2016.02.041] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
5 de Biase S, Nilo A, Bernardini A, Gigli GL, Valente M, Merlino G. Timing use of novel anti-epileptic drugs: is earlier better? Expert Review of Neurotherapeutics 2019;19:945-54. [DOI: 10.1080/14737175.2019.1636649] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
6 Rohracher A, Kalss G, Kuchukhidze G, Neuray C, Leitinger M, Höfler J, Kreidenhuber R, Rossini F, Volna K, Mauritz M, Poppert N, Lattanzi S, Brigo F, Trinka E. New anti-seizure medication for elderly epilepsy patients - a critical narrative review. Expert Opin Pharmacother 2021;22:621-34. [PMID: 33111598 DOI: 10.1080/14656566.2020.1843636] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
7 Zaccara G, Lattanzi S. Comorbidity between epilepsy and cardiac arrhythmias: Implication for treatment. Epilepsy Behav 2019;97:304-12. [PMID: 31279643 DOI: 10.1016/j.yebeh.2019.05.038] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
8 Kropeit D, Johnson M, Cawello W, Rudd GD, Horstmann R. Lacosamide cardiac safety: a thorough QT/QTc trial in healthy volunteers. Acta Neurol Scand 2015;132:346-54. [DOI: 10.1111/ane.12416] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
9 Bauer S, Willems LM, Paule E, Petschow C, Zöllner JP, Rosenow F, Strzelczyk A. The efficacy of lacosamide as monotherapy and adjunctive therapy in focal epilepsy and its use in status epilepticus: clinical trial evidence and experience. Ther Adv Neurol Disord 2017;10:103-26. [PMID: 28382109 DOI: 10.1177/1756285616675777] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
10 Bainbridge J, De Backer M, Eckhardt K, Tennigkeit F, Bongardt S, Sen D, Werhahn KJ, Shaibani A, Faught E. Safety and tolerability of lacosamide monotherapy in the elderly: A subgroup analysis from lacosamide trials in diabetic neuropathic pain. Epilepsia Open 2017;2:415-23. [PMID: 29588972 DOI: 10.1002/epi4.12079] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
11 Wu T, Chuang YC, Huang HC, Lim SN, Hsieh PF, Lee WT, Cheng MY, Tsai MH, Jou SB, Chang CW, Hsieh HY, Du X, Hellot S, McClung C, Hung C. A prospective, multicenter, noninterventional study in Taiwan to evaluate the safety and tolerability of lacosamide as adjunctive therapy for epilepsy in clinical practice. Epilepsy Behav 2020;113:107464. [PMID: 33152580 DOI: 10.1016/j.yebeh.2020.107464] [Reference Citation Analysis]
12 Ferreira JA, Le Pichon JB, Abdelmoity AT, Dilley D, Dedeken P, Daniels T, Byrnes W. Safety and tolerability of adjunctive lacosamide in a pediatric population with focal seizures - An open-label trial. Seizure 2019;71:166-73. [PMID: 31374487 DOI: 10.1016/j.seizure.2019.05.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
13 LaPenna P, Tormoehlen LM. The Pharmacology and Toxicology of Third-Generation Anticonvulsant Drugs. J Med Toxicol 2017;13:329-42. [PMID: 28815428 DOI: 10.1007/s13181-017-0626-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
14 Biton V, Gil-Nagel A, Isojarvi J, Doty P, Hebert D, Fountain NB. Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials. Epilepsy Behav 2015;52:119-27. [PMID: 26414341 DOI: 10.1016/j.yebeh.2015.09.006] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 6.3] [Reference Citation Analysis]
15 Lachuer C, Corny J, Bézie Y, Ferchichi S, Durand-Gasselin B. Complete Atrioventricular Block in an Elderly Patient Treated with Low-Dose Lacosamide. Cardiovasc Toxicol 2018;18:579-82. [PMID: 29948594 DOI: 10.1007/s12012-018-9467-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
16 Zaccara G, Lattanzi S, Brigo F. Cardiac adverse effects of antiseizure medications. Expert Opin Drug Saf 2021;:1-12. [PMID: 34942077 DOI: 10.1080/14740338.2022.2023128] [Reference Citation Analysis]
17 Muñoz-lopetegi A, López-gonzález FJ, Rodríguez-osorio X, Pato Pato A, Bellas Lamas P, Abella-corral J, Castro Vilanova MD, Garea MJ, Gil López JA, Ruiz-martínez J, Poza JJ. LACONORTE study: Efficacy and security of lacosamide as first add-on therapy for focal-onset epilepsy in real-life setting. Epilepsy Research 2018;145:51-4. [DOI: 10.1016/j.eplepsyres.2018.05.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
18 Vossler DG, Wechsler RT, Williams P, Byrnes W, Therriault S; ALEX-MT study group. Long-term exposure and safety of lacosamide monotherapy for the treatment of partial-onset (focal) seizures: Results from a multicenter, open-label trial. Epilepsia 2016;57:1625-33. [PMID: 27528101 DOI: 10.1111/epi.13502] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
19 Kim HK, Lee H, Bae EK, Kim DW. Cardiac effects of rapid intravenous loading of lacosamide in patients with epilepsy. Epilepsy Res 2021;176:106710. [PMID: 34265537 DOI: 10.1016/j.eplepsyres.2021.106710] [Reference Citation Analysis]
20 Bravo P, Vaddiparti A, Hirsch LJ. Pharmacotherapy for Nonconvulsive Seizures and Nonconvulsive Status Epilepticus. Drugs 2021;81:749-70. [PMID: 33830480 DOI: 10.1007/s40265-021-01502-4] [Reference Citation Analysis]
21 Rosenow F, Brandt C, Bozorg A, Dimova S, Steiniger-Brach B, Zhang Y, Ferrò B, Holmes GL, Kälviäinen R. Lacosamide in patients with epilepsy of cerebrovascular etiology. Acta Neurol Scand 2020;141:473-82. [PMID: 32068241 DOI: 10.1111/ane.13230] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Scott LJ. Lacosamide: A Review in Focal Seizures in Patients with Epilepsy. Drugs 2015;75:2143-54. [DOI: 10.1007/s40265-015-0514-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
23 Li J, Sun M, Wang X. The adverse-effect profile of lacosamide. Expert Opin Drug Saf 2020;19:131-8. [PMID: 31914330 DOI: 10.1080/14740338.2020.1713089] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]